Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Massimo Loda, M.D.

Co-Author

This page shows the publications co-authored by Massimo Loda and Lorelei Mucci.
Connection Strength

6.378
  1. Association of Prediagnostic Blood Metabolomics with Prostate Cancer Defined by ERG or PTEN Molecular Subtypes. Cancer Epidemiol Biomarkers Prev. 2021 05; 30(5):1000-1008.
    View in: PubMed
    Score: 0.237
  2. Gene Expression Pathways in Prostate Tissue Associated with Vigorous Physical Activity in Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2021 04; 30(4):751-756.
    View in: PubMed
    Score: 0.236
  3. Genetic ablation of FASN attenuates the invasive potential of prostate cancer driven by Pten loss. J Pathol. 2021 03; 253(3):292-303.
    View in: PubMed
    Score: 0.234
  4. Multiplex Immunofluorescence in Formalin-Fixed Paraffin-Embedded Tumor Tissue to Identify Single-Cell-Level PI3K Pathway Activation. Clin Cancer Res. 2020 11 15; 26(22):5903-5913.
    View in: PubMed
    Score: 0.230
  5. Tumor protein expression of the DNA repair gene BRCA1 and lethal prostate cancer. Carcinogenesis. 2020 07 14; 41(7):904-908.
    View in: PubMed
    Score: 0.227
  6. Inferior Cancer Survival for Men with Localized High-grade Prostate Cancer but Low Prostate-specific Antigen. Eur Urol. 2020 10; 78(4):637-639.
    View in: PubMed
    Score: 0.227
  7. Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer. Clin Cancer Res. 2020 03 01; 26(5):1086-1093.
    View in: PubMed
    Score: 0.217
  8. Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate. Mol Cancer Res. 2019 02; 17(2):446-456.
    View in: PubMed
    Score: 0.202
  9. Height, Obesity, and the Risk of TMPRSS2:ERG-Defined Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2018 02; 27(2):193-200.
    View in: PubMed
    Score: 0.189
  10. MYC Overexpression at the Protein and mRNA Level and Cancer Outcomes among Men Treated with Radical Prostatectomy for Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2018 02; 27(2):201-207.
    View in: PubMed
    Score: 0.189
  11. Stromal and epithelial transcriptional map of initiation progression and metastatic potential of human prostate cancer. Nat Commun. 2017 09 04; 8(1):420.
    View in: PubMed
    Score: 0.187
  12. Gene expression profiling of prostate tissue identifies chromatin regulation as a potential link between obesity and lethal prostate cancer. Cancer. 2017 Nov 01; 123(21):4130-4138.
    View in: PubMed
    Score: 0.185
  13. The role of tumor metabolism as a driver of prostate cancer progression and lethal disease: results from a nested case-control study. Cancer Metab. 2016; 4:22.
    View in: PubMed
    Score: 0.177
  14. Association of Prostate Cancer Risk Variants with TMPRSS2:ERG Status: Evidence for Distinct Molecular Subtypes. Cancer Epidemiol Biomarkers Prev. 2016 05; 25(5):745-9.
    View in: PubMed
    Score: 0.168
  15. Dietary lycopene intake and risk of prostate cancer defined by ERG protein expression. Am J Clin Nutr. 2016 Mar; 103(3):851-60.
    View in: PubMed
    Score: 0.167
  16. Evaluating a 4-marker signature of aggressive prostate cancer using time-dependent AUC. Prostate. 2015 Dec; 75(16):1926-33.
    View in: PubMed
    Score: 0.162
  17. Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate Cancer. Mol Cancer Res. 2015 Oct; 13(10):1431-40.
    View in: PubMed
    Score: 0.160
  18. Androgen receptor CAG repeat polymorphism and risk of TMPRSS2:ERG-positive prostate cancer. Cancer Epidemiol Biomarkers Prev. 2014 Oct; 23(10):2027-31.
    View in: PubMed
    Score: 0.149
  19. SPINK1 protein expression and prostate cancer progression. Clin Cancer Res. 2014 Sep 15; 20(18):4904-11.
    View in: PubMed
    Score: 0.147
  20. Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERG. J Natl Cancer Inst. 2013 Dec 18; 105(24):1881-90.
    View in: PubMed
    Score: 0.144
  21. Prostate-specific membrane antigen protein expression in tumor tissue and risk of lethal prostate cancer. Cancer Epidemiol Biomarkers Prev. 2013 Dec; 22(12):2354-63.
    View in: PubMed
    Score: 0.142
  22. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2012 Sep; 21(9):1497-509.
    View in: PubMed
    Score: 0.130
  23. mRNA expression signature of Gleason grade predicts lethal prostate cancer. J Clin Oncol. 2011 Jun 10; 29(17):2391-6.
    View in: PubMed
    Score: 0.120
  24. Fatty acid synthase polymorphisms, tumor expression, body mass index, prostate cancer risk, and survival. J Clin Oncol. 2010 Sep 01; 28(25):3958-64.
    View in: PubMed
    Score: 0.114
  25. Genetic variation in RNASEL associated with prostate cancer risk and progression. Carcinogenesis. 2010 Sep; 31(9):1597-603.
    View in: PubMed
    Score: 0.113
  26. Immunohistochemical expression of BRCA1 and lethal prostate cancer. Cancer Res. 2010 Apr 15; 70(8):3136-9.
    View in: PubMed
    Score: 0.112
  27. Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol. 2009 Jul 20; 27(21):3459-64.
    View in: PubMed
    Score: 0.105
  28. Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J Natl Cancer Inst. 2009 Apr 01; 101(7):519-32.
    View in: PubMed
    Score: 0.104
  29. Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of beta-catenin in prostate cancer. Lab Invest. 2008 Dec; 88(12):1340-8.
    View in: PubMed
    Score: 0.101
  30. Transcriptional landscape of PTEN loss in primary prostate cancer. BMC Cancer. 2021 Jul 26; 21(1):856.
    View in: PubMed
    Score: 0.061
  31. High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program. Nat Commun. 2019 09 25; 10(1):4358.
    View in: PubMed
    Score: 0.054
  32. A Prospective Study of Intraprostatic Inflammation, Focal Atrophy, and Progression to Lethal Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2019 12; 28(12):2047-2054.
    View in: PubMed
    Score: 0.054
  33. Family history of prostate cancer and the incidence of ERG- and phosphatase and tensin homolog-defined prostate cancer. Int J Cancer. 2020 05 15; 146(10):2694-2702.
    View in: PubMed
    Score: 0.053
  34. Aneuploidy drives lethal progression in prostate cancer. Proc Natl Acad Sci U S A. 2019 06 04; 116(23):11390-11395.
    View in: PubMed
    Score: 0.052
  35. Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease. Carcinogenesis. 2018 12 31; 39(12):1431-1437.
    View in: PubMed
    Score: 0.051
  36. Transcriptome Deconvolution of Heterogeneous Tumor Samples with Immune Infiltration. iScience. 2018 Nov 30; 9:451-460.
    View in: PubMed
    Score: 0.051
  37. A Prospective Study of Aspirin Use and Prostate Cancer Risk by TMPRSS2:ERG Status. Cancer Epidemiol Biomarkers Prev. 2018 10; 27(10):1231-1233.
    View in: PubMed
    Score: 0.050
  38. Circulating Antioxidant Levels and Risk of Prostate Cancer by TMPRSS2:ERG. Prostate. 2017 May; 77(6):647-653.
    View in: PubMed
    Score: 0.045
  39. Prognostic Utility of a New mRNA Expression Signature of Gleason Score. Clin Cancer Res. 2017 Jan 01; 23(1):81-87.
    View in: PubMed
    Score: 0.044
  40. Vascular morphology differentiates prostate cancer mortality risk among men with higher Gleason grade. Cancer Causes Control. 2016 08; 27(8):1043-7.
    View in: PubMed
    Score: 0.043
  41. Calcium-Sensing Receptor Tumor Expression and Lethal Prostate Cancer Progression. J Clin Endocrinol Metab. 2016 06; 101(6):2520-7.
    View in: PubMed
    Score: 0.042
  42. Pre-diagnostic circulating sex hormone levels and risk of prostate cancer by ERG tumour protein expression. Br J Cancer. 2016 Apr 12; 114(8):939-44.
    View in: PubMed
    Score: 0.042
  43. Risk of prostate cancer-specific death in men with baseline metabolic aberrations treated with androgen deprivation therapy for biochemical recurrence. BJU Int. 2016 Dec; 118(6):919-926.
    View in: PubMed
    Score: 0.042
  44. Overexpression of the Long Non-coding RNA SChLAP1 Independently Predicts Lethal Prostate Cancer. Eur Urol. 2016 10; 70(4):549-552.
    View in: PubMed
    Score: 0.041
  45. A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer. J Natl Cancer Inst. 2016 Feb; 108(2).
    View in: PubMed
    Score: 0.041
  46. Stress-Related Signaling Pathways in Lethal and Nonlethal Prostate Cancer. Clin Cancer Res. 2016 Feb 01; 22(3):765-772.
    View in: PubMed
    Score: 0.041
  47. Comparing Platforms for Messenger RNA Expression Profiling of Archival Formalin-Fixed, Paraffin-Embedded Tissues. J Mol Diagn. 2015 Jul; 17(4):374-81.
    View in: PubMed
    Score: 0.040
  48. Molecular differences in transition zone and peripheral zone prostate tumors. Carcinogenesis. 2015 Jun; 36(6):632-8.
    View in: PubMed
    Score: 0.039
  49. Tumor expression of adiponectin receptor 2 and lethal prostate cancer. Carcinogenesis. 2015 Jun; 36(6):639-47.
    View in: PubMed
    Score: 0.039
  50. The TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancer. Prostate. 2015 Jun 15; 75(9):897-906.
    View in: PubMed
    Score: 0.039
  51. Role of diet in prostate cancer: the epigenetic link. Oncogene. 2015 Sep 03; 34(36):4683-91.
    View in: PubMed
    Score: 0.039
  52. Association of prostate cancer risk variants with gene expression in normal and tumor tissue. Cancer Epidemiol Biomarkers Prev. 2015 Jan; 24(1):255-60.
    View in: PubMed
    Score: 0.038
  53. 5a-Reductase inhibitors and risk of high-grade or lethal prostate cancer. JAMA Intern Med. 2014 Aug; 174(8):1301-7.
    View in: PubMed
    Score: 0.038
  54. Dietary lycopene, angiogenesis, and prostate cancer: a prospective study in the prostate-specific antigen era. J Natl Cancer Inst. 2014 Feb; 106(2):djt430.
    View in: PubMed
    Score: 0.036
  55. Protein expression of PTEN, insulin-like growth factor I receptor (IGF-IR), and lethal prostate cancer: a prospective study. Cancer Epidemiol Biomarkers Prev. 2013 Nov; 22(11):1984-93.
    View in: PubMed
    Score: 0.035
  56. Gleason grade progression is uncommon. Cancer Res. 2013 Aug 15; 73(16):5163-8.
    View in: PubMed
    Score: 0.035
  57. ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients. Genes Dev. 2013 Mar 15; 27(6):683-98.
    View in: PubMed
    Score: 0.034
  58. ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer. J Clin Invest. 2013 Mar; 123(3):1109-22.
    View in: PubMed
    Score: 0.034
  59. Selenoprotein P genetic variants and mrna expression, circulating selenium, and prostate cancer risk and survival. Prostate. 2013 May; 73(7):700-5.
    View in: PubMed
    Score: 0.033
  60. Association of metabolic syndrome with reduced survival among men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Clin Oncol. 2012 Feb 10; 30(5_suppl):56.
    View in: PubMed
    Score: 0.032
  61. Effect of dietary polyunsaturated fatty acids on castration-resistant Pten-null prostate cancer. Carcinogenesis. 2012 Feb; 33(2):404-12.
    View in: PubMed
    Score: 0.031
  62. Prognostic determinants in prostate cancer. Cancer J. 2011 Nov-Dec; 17(6):429-37.
    View in: PubMed
    Score: 0.031
  63. Common polymorphisms in the adiponectin and its receptor genes, adiponectin levels and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2011 Dec; 20(12):2618-27.
    View in: PubMed
    Score: 0.031
  64. Vitamin D receptor protein expression in tumor tissue and prostate cancer progression. J Clin Oncol. 2011 Jun 10; 29(17):2378-85.
    View in: PubMed
    Score: 0.030
  65. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature. 2011 Feb 10; 470(7333):269-73.
    View in: PubMed
    Score: 0.030
  66. Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis. PLoS Genet. 2010 Nov 11; 6(11):e1001204.
    View in: PubMed
    Score: 0.029
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.